Polymorphisms in <i>GSTT1</i> , <i>GSTZ1</i> , and <i>CYP2E1</i> , Disinfection By-products, and Risk of Bladder Cancer in Spain

Abstract

Polymorphisms in key metabolizing enzymes modified DBP-associated bladder cancer risk. The consistency of these findings with experimental observations of GSTT1, GSTZ1, and CYP2E1 activity strengthens the hypothesis that DBPs cause bladder cancer and suggests possible mechanisms as well as the classes of compounds likely to be implicated.